Skip to main content

Advertisement

SpringerLink
Log in

Ocular toxicity of systemic asthma and allergy treatments

  • Published:
Current Allergy and Asthma Reports Aims and scope Submit manuscript

Abstract

Systemic medications, such as antihistaminic and antiin .ammatory agents used in the treatment of asthma and allergy, may have adverse effects on the eye. The major adverse effects on the eye have included cataracts, glaucoma, and tear-.lm dysfunction (dry-eye syndrome). The use of inhaled corticosteroids (bronchial and nasal) has been associated with mild systemic effects when compared with oral corticosteroids. The development of cataracts and glaucoma has been more commonly associated with earlier “hard” oral and inhaled steroids that affected individuals with an inherent high susceptibility or those who used them for several years. Whereas oral antihistamines commonly have an effect on allergies within hours, they also may exacerbate dry-eye complaints that commonly complicate symptoms with various forms of tear .lm dysfunction or conjunctival hyperreactivity. Clinicians should be aware that other systemic agents may complicate their attempts to maximize the treatment of ocular allergies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Allen DB, Bielory L, Derendorf H, et al.: Inhaled corticosteroids: past lessons and future issues. J Allergy Clin Immunol 2003, 112:S1-S40. Provides a multiorgan overview of the effects of steroids and considers the future development of “soft” steroids with a lower clinical adverse profile.

    Article  PubMed  CAS  Google Scholar 

  2. Kewley GD: Possible association between beclomethasone diproprionate aerosol and cataracts. Aust Paediatr J 1980, 16:117–118.

    PubMed  CAS  Google Scholar 

  3. Black R, Oglesby R, von Sallmann L, Bunim J: Posterior subcapsular cataracts induced by corticosteroids in patients with rheumatoid arthritis. JAMA 1960, 174:150–171.

    Google Scholar 

  4. Bhagat RG, Chai H: Development of posterior subcapsular cataracts in asthmatic children. Pediatrics 1984, 73:626–630.

    PubMed  CAS  Google Scholar 

  5. Rooklin A, Lampert S, Jaeger E, et al.: Posterior subcapsular cataracts in steroid requiring asthmatic children. J Allergy Clin Immunol 1979, 63:383–386.

    Article  PubMed  CAS  Google Scholar 

  6. Urban R, Cotlier E: Corticosteroid induced cataracts. Surv Ophthalmol 1986, 31:102–110.

    Article  PubMed  CAS  Google Scholar 

  7. Forman AR, Loreto JA, Tina LU: Reversibility of corticosteroid- associated cataracts in children with the nephrotic syndrome. Am J Ophthalmol 1977, 84:75–78.

    PubMed  CAS  Google Scholar 

  8. Oglesby R, Black R, von Sallmann L, Bunim J: Cataracts in patients with rheumatic diseases treated with corticosteroids. Arch Ophthalmol 1961, 66:41–46.

    Google Scholar 

  9. Nassif E, Weinberger M, Sherman B, Brown K: Extrapulmonary effects of maintenance corticosteroid therapy with alternate-day prednisone and inhaled beclomethasone in children with chronic asthma. J Allergy Clin Immunol 1987, 80:518–529.

    Article  PubMed  CAS  Google Scholar 

  10. Toogood JH, Markov AE, Baskerville J, Dyson C: Association of ocular cataracts with inhaled and oral steroid therapy during long-term treatment of asthma. J Allergy Clin Immunol 1993, 91:571–579.

    Article  PubMed  CAS  Google Scholar 

  11. Simons FE, Persaud MP, Gillespie CA, et al.: Absence of posterior subcapsular cataracts in young patients treated with inhaled glucocorticoids. Lancet 1993, 342:776–778.

    Article  PubMed  CAS  Google Scholar 

  12. Russell G: Inhaled corticosteroid therapy in children: an assessment of the potential for side effects. Thorax 1994, 49:1185–1188.

    Article  PubMed  CAS  Google Scholar 

  13. Cumming R, Mitchell P, Leeder S: Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med 1997, 337:8–14.

    Article  PubMed  CAS  Google Scholar 

  14. Garbe E, Suissa S, LeLorier J:. Association of inhaled corticosteroid use with cataract extraction in elderly patients. JAMA 1998, 280:539–543.

    Article  PubMed  CAS  Google Scholar 

  15. Hanania NA, Chapman KR, Kesten S: Adverse effects of inhaled corticosteroids. Am J Med 1995, 98:196–208.

    Article  PubMed  CAS  Google Scholar 

  16. Dluhy RG: Effect of inhaled beclomethasone dipropionate and budesonide on adrenal function, skin changes and cataract formation. Respir Med 1998, 92(Suppl B):15–23.

    Article  PubMed  Google Scholar 

  17. Agertoft L, Larsen FE, Pedersen S: Posterior subcapsular cataracts, bruises and hoarseness in children with asthma receiving long-term treatment with inhaled budesonide. Eur Respir J 1998, 12:130–135.

    Article  PubMed  CAS  Google Scholar 

  18. Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group.N Engl J Med 2000, 343:1054–1063.

  19. Moller C, Ahlstrom H, Henricson KA, et al.: Safety of nasal budesonide in the long-term treatment of children with perennial rhinitis. Clin Exp Allergy 2003, 33:816–822.

    Article  PubMed  CAS  Google Scholar 

  20. Jick SS, Vasilakis-Scaramozza C, Maier WC: The risk of cataract among users of inhaled steroids. Epidemiology 2001, 12:229–234.

    Article  PubMed  CAS  Google Scholar 

  21. Bisgaard H, Allen D, Milanowski J, et al.: Twelve-month safety and efficacy of inhaled.uticasone propionate in children aged 1 to 3 years with recurrent wheezing. Pediatrics 2004, 113:e87-e94.

    Article  PubMed  Google Scholar 

  22. Sheffer AL, Silverman M, Woolcock AJ, et al.: Long-term safety of once-daily budesonide in patients with earlyonset mild persistent asthma: results of the Inhaled Steroid Treatment as Regular Therapy in Early Asthma (START) study. Ann Allergy Asthma Immunol 2005, 94:48–54.

    PubMed  CAS  Google Scholar 

  23. Tripathi RC, Parapuram SK, Tripathi BJ, et al.: Corticosteroids and glaucoma risk. Drugs Aging 1999, 15:439–450.

    Article  PubMed  CAS  Google Scholar 

  24. Zhang X, Clark AF, Yorio T: Regulation of glucocorticoid responsiveness in glaucomatous trabecular meshwork cells by glucocorticoid receptor-beta. Invest Ophthalmol Vis Sci 2005, 46:4607–4616.

    Article  PubMed  Google Scholar 

  25. Stokes J, Walker BR, Campbell JC, et al.: Altered peripheral sensitivity to glucocorticoids in primary open-angle glaucoma. Invest Ophthalmol Vis Sci 2003, 44:5163–5167.

    Article  PubMed  Google Scholar 

  26. Dreyer EB: Inhaled steroid use and glaucoma. N Engl J Med 1993, 329:1822.

    Article  PubMed  CAS  Google Scholar 

  27. Opatowsky I, Feldman RM, Gross R, Feldman ST: Intraocular pressure elevation associated with inhalation and nasal corticosteroids. Ophthalmology 1995, 102:177–179.

    PubMed  CAS  Google Scholar 

  28. Desnoeck M, Casteels I, Casteels K: Intraocular pressure elevation in a child due to the use of inhalation steroids— a case report. Bull Soc Belge Ophtalmol 2001, 280:97–100.

    PubMed  Google Scholar 

  29. Hartung J, Knapp G: [A re-analysis of the Blue Mountain eye study on the risk of cataracts from inhaled corticosteroids. A contribution to objectifying the discussion]. Pneumologie 1999, 53:411–416.

    Article  PubMed  CAS  Google Scholar 

  30. Garbe E, LeLorier J, Boivin JF, Suissa S: Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma. JAMA 1997, 277:722–727.

    Article  PubMed  CAS  Google Scholar 

  31. Behbehani AH, Owayed AF, Hijazi ZM, et al.: Cataract and ocular hypertension in children on inhaled corticosteroid therapy. J Pediatr Ophthalmol Strabismus 2005, 42:23–27.

    PubMed  Google Scholar 

  32. Duh MS, Walker AM, Lindmark B, Laties AM: Association between intraocular pressure and budesonide inhalation therapy in asthmatic patients. Ann Allergy Asthma Immunol 2000, 85:356–361.

    PubMed  CAS  Google Scholar 

  33. Dibildox J:. Safety and efficacy of mometasone furoate aqueous nasal spray in children with allergic rhinitis: results of recent clinical trials. J Allergy Clin Immunol 2001, 108(1 Suppl):S54-S58.

    Article  PubMed  CAS  Google Scholar 

  34. Tripathi RC, Kipp MA, Tripathi BJ, et al.: Ocular toxicity of prednisone in pediatric patients with inflammatory bowel disease. Lens Eye Toxic Res 1992, 9:469–482.

    PubMed  CAS  Google Scholar 

  35. Bui CM, Chen H, Shyr Y, Joos KM: Discontinuing nasal steroids might lower intraocular pressure in glaucoma. J Allergy Clin Immunol 2005, 116:1042–1047. This study demonstrated the effect of discontinuing nasal steroid sprays on intraocular pressure (intraocular pressure) in patients with glaucoma that resulted in a significant reduction (4 mm) in IOP. Nasal steroids might contribute to IOP increase, and inquiry as to whether a patient has glaucoma before medication initiation is warranted.

    Article  PubMed  CAS  Google Scholar 

  36. Berger W, Abelson MB, Gomes PJ, et al.: Effects of adjuvant therapy with 0.1% olopatadine hydrochloride ophthalmic solution on quality of life in patients with allergic rhinitis using systemic or nasal therapy. Ann Allergy Asthma Immunol 2005, 95:361–371.

    Article  PubMed  CAS  Google Scholar 

  37. Bielory L, Lien KW, Bigelsen S: Efficacy and tolerability of newer antihistamines in the treatment of allergic conjunctivitis. Drugs 2005, 65:215–228.

    Article  PubMed  CAS  Google Scholar 

  38. Bielory L, Ghafoor S: Histamine receptors and the conjunctiva. Curr Opin Allergy Clin Immunol 2005, 5:437–440. The effect of histamine on conjunctival H1 receptors appears to be the primary target for ocular allergy treatment, as it is primarily involved in ocular pruritus. Oral and topical antihistamines with multiple histamine receptor binding activities may provide an improved treatment paradigm for the various signs and symptoms of ocular allergy. The review also identifies histamine H1, H2, and H3 receptor affinities of the various commonly used antihistamines.

    Article  PubMed  CAS  Google Scholar 

  39. Thorig L, Halperin M, van Haeringen NJ: The fine-thread method: lacrimation test for measuring ocular sideeffects of drugs in the rat. Doc Ophthalmol 1983, 56:35–39.

    Article  PubMed  CAS  Google Scholar 

  40. Thorig L, Halperin M, van Haeringen NJ: Cotton-thread tear test: an experimental study for testing drugs suspected of side effects on lacrimation. Doc Ophthalmol 1984, 58:307–315.

    Article  PubMed  CAS  Google Scholar 

  41. Horak F, Jager S, Berger U: Onset and duration of the effects of three antihistamines in current use—astemizole, loratadine and terfenadine forte—studied during prolonged, controlled allergen challenges in volunteers. J Int Med Res 1992, 20:422–434.

    PubMed  CAS  Google Scholar 

  42. Welch D, Ousler GW 3rd, Nally LA, et al.: Ocular drying associated with oral antihistamines (loratadine) in the normal population—an evaluation of exaggerated dose effect. Adv Exp Med Biol 2002, 506(Pt B):1051–1055.

    PubMed  CAS  Google Scholar 

  43. Ousler GW, Wilcox KA, Gupta G, Abelson MB: An evaluation of the ocular drying effects of 2 systemic antihistamines: loratadine and cetirizine hydrochloride. Ann Allergy Asthma Immunol 2004, 93:460–464. Oral antihistamines, such as loratadine and cetirizine hydrochloride, have proven efficacious in the control of many allergic conditions; however, these agents have also been associated with inducing signs and symptoms associated with ocular dryness, including increased corneal and conjunctival staining, decreased tear-.lm breakup time, and increased ocular discomfort in healthy individuals.

    PubMed  CAS  Google Scholar 

  44. Howell G 3rd, West L, Jenkins C, et al.: In vivo antimuscarinic actions of the third generation antihistaminergic agent, desloratadine. BMC Pharmacol 2005, 5:13.

    Article  PubMed  CAS  Google Scholar 

  45. Liu H, Farley JM: Effects of.rst and second generation antihistamines on muscarinic induced mucus gland cell ion transport. BMC Pharmacol 2005, 5:8.

    Article  PubMed  CAS  Google Scholar 

  46. Grumetto L, Cennamo G, Del Prete A, et al.: Pharmacokinetics of cetirizine in tear.uid after a single oral dose. Clin Pharmacokinet 2002, 41:525–531.

    Article  PubMed  CAS  Google Scholar 

  47. Tinkelman DG, Reed CE, Nelson HS, Offord KP: Aerosol beclomethasone dipropionate compared with theophylline as primary treatment of chronic, mild to moderately severe asthma in children. Pediatrics 1993, 92:64–77.

    PubMed  CAS  Google Scholar 

  48. Volovitz B, Amir J, Malik H, et al.: Growth and pituitary-adrenal function in children with severe asthma treated with inhaled budesonide. N Engl J Med 1993, 329:1703–1708.

    Article  PubMed  CAS  Google Scholar 

  49. Ozturk F, Yuceturk AV, Kurt E, et al.: Evaluation of intraocular pressure and cataract formation following the long-term use of nasal corticosteroids. Ear Nose Throat J 1998, 77:846–848, 850-841.

    PubMed  CAS  Google Scholar 

  50. Cumming RG, Mitchell P: Inhaled corticosteroids and cataract: prevalence, prevention and management. Drug Saf 1999, 20:77–84.

    Article  PubMed  CAS  Google Scholar 

  51. Wagener JS, Wojtczak HA: Inhaled steroids in children: risks versus rewards. J Pediatr 1998, 132(3 Pt 1):381–383.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Allergy, Immunology & Rheumatology, UMDNJ—New Jersey Medical School, 90 Bergen Street, DOC Suite 4700, 07103, Newark, NJ, USA

    Leonard Bielory MD

Authors
  1. Leonard Bielory MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bielory, L. Ocular toxicity of systemic asthma and allergy treatments. Curr Allergy Asthma Rep 6, 299–305 (2006). https://doi.org/10.1007/s11882-006-0063-y

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11882-006-0063-y

Keywords

Search

Navigation